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In mammals, male sex is determined by the Y-chromosomal
gene Sry (sex-determining region of Y chromosome). The
expression of Sry and subsequently Sox9 (SRY box containing
gene 9) in precursors of the supporting cell lineage results in the
differentiation of these cells into Sertoli cells. Sertoli cells in
turn orchestrate the development of all other male-specific cell
types. To ensure that Sertoli cells differentiate in sufficient
numbers to induce normal testis development, the early testis
produces prostaglandin D2 (PGD2), which recruits cells of the
supporting cell lineage to a Sertoli cell fate. Here we show that
the gene encoding prostaglandin D synthase (Pgds), the enzyme
that produces PGD2, is expressed in Sertoli cells immediately
after the onset of Sox9 expression. Promoter analysis in silico
and in vitro identified a paired SOX/SRY binding site. Interest-
ingly, only SOX9, andnot SRY,was able to bind as a dimer to this
site and transactivate the Pgds promoter. In line with this, a
transgenic mouse model showed that Pgds expression is not
affected by ectopic Sry expression. Finally, chromatin immuno-
precipitation proved that SOX9 but not SRY binds to the Pgds
promoter in vivo.
Sexual differentiation in mammals is unique in that an indif-
ferent organ system, including gonads, genital tracts, and exter-
nal genitalia, has the potential to develop in two completely
different directions, either down themale pathway or down the
female pathway. In mice, the decision as to which pathway to
follow takes place between 10.5 and 12.5 days post coitum
(dpc),3 when the gene Sry (sex-determining gene on the
Y-chromosome) is expressed in the genital ridge of an XY ani-
mal or not expressed, as in the case of an XX animal. The
expression of Sry drives the differentiation of the genital ridge
into a testis rather than an ovary, which in turn directs all sec-
ondary sexual differentiation via secretion ofmale-specific hor-
mones (for review see Ref. 1).
SRY belongs to the family of SOX transcription factors that
are characterized by the high mobility group DNA binding
domain. It is expressed specifically in the supporting cell lineage
that gives rise to immature Sertoli cells in the developing testis.
The expression of Sry resembles a wave, starting in the center
of the genital ridge, expanding to the poles and turning off first
at the anterior polewith the last SRY-positive cells being detect-
able at the posterior pole at around 12.5 dpc (2–6). Almost
immediately after Sry, another gene of the Sox family, Sox9, is
expressed in the same cells following a similar wave of up-reg-
ulation, but unlike Sry, its expression continues throughout tes-
tis development (7–9). Subsequently, SOX9-positive cells dif-
ferentiate into Sertoli cells, which form the testis cords by
enclosing clusters of germcells. Sertoli cells then coordinate the
differentiation of all other testis-specific cell types such as the
steroidogenic Leydig cells within the interstitium and peritubu-
lar myoid cells, which surround Sertoli cells and thereby take
part in testis cord formation. It has been shown that both Sry
and Sox9 are necessary and sufficient for male development in
mice and in humans (10–17).
Both SRY and SOX9 bind sequence-specifically to DNA via
their highly conserved high mobility group domains. Consis-
tently, in vitro experiments have shown that both factors rec-
ognize essentially the same DNAmotifs with very similar affin-
ities and induce sharp bends at similar angles (18, 19). This,
together with the fact that Sry and Sox9 are expressed in the
same cells in overlapping time windows during gonad develop-
ment, presents a major challenge in identifying specific targets
for each factor. Although SOX9 contains two well defined
transactivation domains and has been implicated in the up-reg-
ulation of several genes such as anti-Mu¨llerian hormone (Amh
(7, 20, 21)) and Vanin-1 (Vnn1 (22)), no in vivo target gene for
SRY has been identified to date, and it is even unclear whether
SRY functions as a transcriptional activator and/or repres-
sor. The best candidate so far for being an authentic SRY
target is Sox9 itself. However, experimental proof has not
been forthcoming.
The direct or indirect up-regulation of Sox9 expression by
SRY is crucial for testis development. Studies have shown that
in XX↔ XY chimeric mouse embryos, the ratio of XX to XY
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cells is 50:50 in all tissues, the only exception being Sertoli
cells. Thesewere found to bemore than 90%XY, indicating that
the differentiation of Sertoli cells needs the presence of the Y
chromosome (23), and therefore, SRY acts cell-autonomously.
However, these experiments also imply that Sry is not essential
for the differentiation of all Sertoli cells. XX cells were recruited
to differentiate into Sertoli cells contributing almost one-tenth
of the total number of Sertoli cells. Thus, it is not surprising that
in addition to the cell-autonomous mechanism, at least one
non-cell-autonomousmechanism exists to ensure the differen-
tiation of sufficient Sertoli cells to a level above the estimated
threshold of 20% (24, 25) to guarantee testis differentiation.We
and others have shown that this non-cell-autonomous mecha-
nism involves prostaglandin D2 (PGD2 (6, 26, 27)), produced by
the enzyme prostaglandin D synthase (PGDS), which catalyzes
the isomerization of PGH2, a common precursor of several
prostanoids. PGD2 has been shown to play a role in various
physiological and pathological functions as an endogenous
somnogen, anti-coagulant, vasodilator, broncho-constrictor
and as an allergic and inflammatory mediator released from
mast cells (for review see Ref. 28).
Here we show that Pgds is expressed in Sertoli cells shortly
after the expression of Sry and Sox9 in a similar dynamic wave.
Biochemical, cell culture, and genetic experiments indicate that
this up-regulation is mediated by SOX9, but not SRY, via a
paired SOX recognition site within the Pgds 5-flanking region.
Furthermore, chromatin immunoprecipitation (ChIP) assays
confirm that SOX9 binds in vivo to the identified regulatory
region.
EXPERIMENTAL PROCEDURES
Animals andCell Lines—Embryoswere collected from timed
matings of the SwissQuackenbush outbred strain, with noon of
the day on which the mating plug was observed designated as
0.5 dpc. For more accurate staging, the tail somite (ts) stage of
the embryowas determined by counting the number of somites
posterior to the hind limb (2). Using this method, 10.5 dpc
corresponds to 8 ts, 11.5 dpc corresponds to 18 ts, and 12.5
dpc corresponds to 30 ts. Human embryonic kidney (HEK) 293
cells were grown in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% fetal bovine serum (Cam-
brex), 1 penicillin-streptomycin (Invitrogen), and 2 mM glu-
tamine (Invitrogen) at 37 °C in 5% CO2.
In Situ Hybridization—The probes for Sox9 (29) and Pgds
(27) were made as described previously. Section in situ hybrid-
ization was performed on 7-m sections of paraformaldehyde-
fixed, paraffin-embedded embryos. Sections were dewaxed,
rehydrated, and incubated in 5g/ml proteinaseK for 20min at
room temperature. After washing in PBS, sections were refixed
with 4% paraformaldehyde for 10 min at room temperature,
acetylated, and prehybridized with hybridization solution (50%
formamide, 5 SSC, 5Denhardt’s, 250g/ml yeast RNA, 500
g/ml herring sperm DNA) for 2 h at room temperature.
Hybridization (hybridization solution 0.5 g/ml probe) was
performed overnight at 60 °C. Slides were washed in
5 SSC for 5min, 0.2 SSC for 1 h at 60 °C, 0.2 SSC for 5min
at room temperature and NT buffer (150 mM NaCl, 50 mM
Tris-HCl, pH 7.5) for 5 min at room temperature before incu-
bating for 2 h with blocking solution (10% heat-inactivated
sheep serum in NT buffer) in a humidified chamber. Anti-
digoxigenin antibody (Roche Applied Science) at 1:2000 dilu-
tion in blocking solution was added to the slides and incubated
overnight at 4 °C. Unbound antibodies were removed by wash-
ing three times in NT buffer. Sections were equilibrated in
NTM buffer (100 mM NaCl, 100 mM Tris-HCl, pH 9.5, 50 mM
MgCl2) and incubated in color solution (3.5 l of 5-bromo-4-
chloro-3-indolyl phosphate (Roche Applied Science), 3.5 l of
nitro blue tetrazolium (Roche Applied Science) per ml of NTM
buffer) until purple staining was satisfactory. Whole-mount in
situ hybridization was carried out essentially as described by
Ref. 30.
Electrophoretic Mobility Shift Assay (EMSA)—EMSA analy-
sis was performed as described previously (31) using recombi-
nant, bacterially expressed GST fusion proteins of the full-
length mouse SRY, SOX9, and SOX2. Recombinant plasmids
were constructed by using the vector pGEX-KG (32). Oligo-
nucleotides harboring SOX-A/-B sites had the following
sequence: 5-CCAAATGTTCAAGGCACAAATGGTGCT
TTG TGT TCC CTG CTG G-3; harboring SOX-C site,
5-GGT AGG GCT TGT GAG AAG CAG G-3; mut-A
(mutated nucleotides are underlined), 5-CCAAATGTTCAA
GGG ACG TGT GGT GCT TTG TGT TCC CTG CTG G-3;
mut-B, 5-CCA AAT GTT CAA GGC ACA AAT GGT GCT
TCT GCA CCC CTG CTG G-3; mut-AB, 5-CCA AAT GTT
CAA GGG ACG TGT GGT GCT TCT GCA CCC CTG
CTG G-3. Oligonucleotides were annealed and subsequently
labeled using [-32P]ATP and T4 polynucleotide kinase (Roche
Applied Science) for 1 h at 37 °C and purified using Nick col-
umns (Amersham Biosciences). Binding reactions were per-
formed by using 20 ng of purified protein and 3000 cpm of
end-labeled probe.
Luciferase Assays—HEK293 cells were plated at 3 105/well
in 12-well plate 24 h before transfection. The cells were trans-
fected in triplicates with the relevant combination of plasmids
using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocol. Each well received 800 ng of luciferase
reporter plasmid (pGL2-Basic without or with the wild type or
mutated Pgds promoter fragment), increasing amounts (32,
80, 200 ng) of expression plasmid (pSGSox9 (9) or pcHASry
(33)), and 600 ng of -galactosidase expression plasmid
pCH110 as an internal control. The empty pcHA vector was
added to equalize amounts of transfected plasmid DNA con-
centrations. Cells were harvested 24 h after transfection and
assayed for luciferase and -galactosidase activity as
described previously (7). To verify expression of SOX9 and
SRY,Western blot analysis with antibodies specific for SOX9
(6) and the hemagglutinin tag (Sigma) was performed as
described previously (34). Values were normalized for trans-
fection efficiency according to -galactosidase activity and
with respect to the effects of the expression constructs on the
empty pGL2-Basic reporter plasmid. Three independent
experiments were performed.
ChIP—Male and female genital ridges (gonad  mesone-
phros) were dissected from 500 staged mouse embryos (one
genital ridge at 11.5 dpc yields 1 g of protein) in cold PBS,
and a single cell suspension was prepared by passaging several
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times through a 21-gauge needle. Cells were collected by cen-
trifugation, and proteins and DNA were cross-linked by incu-
bating the cells in 1% formaldehyde/PBS for 10 min at room
temperature. Reactionwas stopped by the addition of glycine in
a final concentration of 0.125 M. Cells were washed three times
with PBS, collected by centrifugation, resuspended in hypo-
tonic lysis buffer (150 mMNaCl, 1% Nonidet P40, 0.1% SDS, 50
mM Tris-HCl, pH 8), and sonicated to shear DNA into frag-
ments 2 kb. Insoluble material was removed by centrifuga-
tion, and the extract was precleared with 30 l of preswollen
protein A-Sepharose (Amersham Biosciences) for 1 h at 4 °C to
reduce nonspecific background. The precleared extract was
split into two equal aliquots and incubated with either anti-
mouse SRY or anti-mouse SOX9 antibodies (6) at 4 °C over-
night. After incubation with 30 l of preswollen protein
A-Sepharose for 2 h at 4 °C, the immunoprecipitates were
washed three timeswith sonication buffer and oncewithTE (10
mMTris-HCl, pH8, 1mMEDTA), and protein-DNAcomplexes
eluted by incubation twicewith 100l of elution buffer (1%SDS
in TE) at 37 °C for 20 min with vigorous shaking. Co-immuno-
precipitated DNA was purified by 0.5 mg/ml proteinase K
digest (overnight at 55 °C), phenol/chloroform extraction, and
washing with Microcon YM-100 filter tubes (Millipore). Iden-
tity of the amplified fragments was verified by sequencing.
Primers used to investigate the enrichment of Pgds promoter
fragments by PCR were as follows: PCR1.F, 5-GTCGACCAG
AAATAACTTTAGAGAAGAAA-3; PCR1.R, 5-TTAAGC
TTC CTG TGT GTG GGG TCC TGT A-3; PCR2.F, 5-TTG
TCG ACC AGG GTA GAG TGC GTG AGC TTC TT-3;
PCR2.R, 5-GGA AGC TTG CGC TTC CCT GCT GCT
GGA AA-3.
RESULTS
Pgds Expression in DevelopingMouse Testes—To address the
question of how the expression of Pgds is regulated in the fetal
gonad, we first compared Pgds and Sox9 expression in detail by
whole-mount in situ hybridization (ISH) analysis of ts-staged
mouse genital ridges from 13 to 21 ts. At each developmental
stage, left and right genital ridges from the same embryo were
assessed in parallel for Pgds and Sox9 expression. Pgds tran-
scripts were first detected in the center of the testis at 17 ts (Fig.
1A), shortly after the onset of Sox9 expression at 15 ts. Subse-
quently, the expression domain ofPgds expanded to include the
anterior and posterior poles. This dynamic, wave-like expres-
sion pattern closely resembles those of Sry and Sox9 in the
embryonic testis (Figs. 1A, and 5,A andB) (3, 6, and 7).Pgdswas
not detected in the ovary at any investigated stages (data not
shown).
To identify the cell type that express Pgds, section ISH was
carried out on whole embryos from 11.5 to 14.5 dpc using an
RNA probe specific for Pgds in comparison with the germ cell-
specific marker geneOct4. At all stages, Pgds, like Sry and Sox9,
was expressed by Sertoli cells but not by germ or interstitial
cells (Fig. 1B, left panels, and data not shown), whereas Oct4
showed the expected expression in germ cells only (Fig. 1B,
right panels).
Identification of the Mouse Pgds Promoter—Our expression
analysis suggested that SRY and/or SOX9 might directly regu-
late Pgds transcription. To test this hypothesis, we compared
the genomic region of mouse Pgds with that of human and dog
by means of the ECR (evolutionary conserved region) browser.
Approximately 600 bp 5 of the transcription start site was
found to be highly conserved between human and mouse and
300 bp between human, mouse, and dog (Fig. 2A). Cloning
and sequence analysis of the conserved 600-bp fragment
revealed three putative SRY/SOXbinding sites (Fig. 2B). Twoof
FIGURE 1. ExpressionprofilingofPgds in comparisonwith Sox9 andOct4.
A, whole-mount in situ hybridizations for Pgds (left gonads) in comparison
with Sox9 (right gonads) were performed on XY urogenital ridges collected
from embryos between 13 and 21 ts. Expression of Pgds started in the center
of the genital ridges between 15 and 17 ts, only a fewhours after Sox9 expres-
sion (between 13 and 15 ts), before extending to the poles (marked by arrow-
heads). B, in situ hybridization on sagittal paraffin sections showed Pgds
expression specifically in Sertoli cells in the embryonic testis at 14.5 dpc,
whereasOct4was expressed by germ cells only. The boxed areas indicate the
magnified area in the panel below. The dotted line demarcates a testis cord.
Scale bars, 200 m (upper panel), 100 m (middle panel), and 50 m (bottom
panel).
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these binding sites (SOX-A and SOX-B) were separated by 4 bp
and arranged in opposite orientation, representing a so-called
paired SOX site similar to the sites identified in the Col2a1,
matrilin-1, Col11a2, and Col27a1 promoters (7, 35–38). The
third SOX site was an isolated, single site.
Characterization of the SOX Binding Sites within the Pgds
Promoter—To determine whether SRY and/or SOX9 protein is
able to bind to these putative binding sites, we performed
EMSAs using labeled duplex oligonucleotides that encom-
passed the paired SOX sites and the single SOX site, respec-
tively (Fig. 2B). After incubation of these oligonucleotides, bac-
terially expressed GST-SRY fusion protein was bound to the
paired binding sites (SOX-A and SOX-B), forming one com-
plex, even with increasing amounts of protein (Fig. 3A, lanes 2
and 3). In contrast, incubation of the labeled oligonucleotide
encompassing SOX-A and SOX-B with SOX9 revealed the for-
mation of two complexes (Fig. 3A, lane 4), presumably corre-
sponding to the binding of SOX9 as amonomer to one site or as
a dimer to both sites. NeitherGST alone nor the dissimilar SOX
protein SOX2 bound to the fragment under these conditions
(Fig. 3A, lanes 1 and 5). In contrast, the single SOX site C was
not bound by any of the proteins tested (Fig. 3A, lanes 6–10).
Having identified the paired SOX site within the Pgds pro-
moter, we sought to characterize these binding sites further by
mutation analysis. Introduction of four point mutations in
SOX-A resulted only in a slight reduction of SRY binding when
comparedwith thewild type sequence (Fig. 3B, compare lanes 2
and 5), whereas for SOX9, only monomeric but no longer
dimeric complexes were detected (Fig. 3B, lanes 3 and 6). In
contrast, mutation of SOX-B almost completely abolished
binding of either SRY or SOX9 to the EMSA probe (Fig. 3B,
FIGURE 3. SOX9 and SRY binding to the Pgds promoter. A, EMSA of Pgds
promoter fragments using oligonucleotides constituting SOX-A/-B (left) and
SOX-C site (right), respectively, and GST only (lanes 1 and 6), GST-SRY (50 ng,
lanes 2 and 7; 100 ng, lanes 3 and 8), -SOX9 (lanes 4 and 9), and -SOX2 (lanes 5
and 10) fusion proteins. The arrow indicates SRY binding as a monomer, one
open arrowhead indicates SOX9 binding as a monomer, and a double open
arrowhead indicates SOX9 binding as a dimer to SOX-A/-B. The third putative
SOX/SRY sitewasboundneither byGSTonly, byGST-SRYorGST-SOX9, nor by
GST-SOX2. B, EMSA of wild type (wt, lanes 1–3) or mutated (A-mut, SOX-A
mutated, lanes 4–6; B-mut, SOX-B mutated, lanes 7–9; AB-mut, SOX-A and
SOX-B mutated, lanes 10–12) Pgds promoter fragment harboring the paired
SOX-A/-B site using GST only (lanes 1, 4, 7, and 10), GST-SRY (lanes 2, 5, 8, and
11), and GST-SOX9 (lanes 3, 6, 9, and 12) fusion proteins. The arrow indicates
SRY binding as a monomer, one open arrowhead indicates SOX9 binding as a
monomer, and adouble open arrowhead indicates SOX9binding as a dimer to
SOX-A/-B.Mutationof SOX-Apreventedonly SOX9bindingasdimer,whereas
mutation of SOX-B greatly reduced binding of both GST-SRY and GST-SOX9.
Mutation of both sites completely abolished binding of SRY and SOX9.
FIGURE 2. Sequence analysis of the Pgds promoter. A, using the mouse
sequence as the base, 600 bp (depicted by dark gray bars) 5 to the Pgds
coding region was identified to be conserved between mouse and human,
and300 bp was identified to be conserved betweenmouse and dog using
the ECR browser. Black bars indicate exons e1 to e6. The conserved region is
magnified in a schematic representation below with the three identified
putative SRY/SOX binding sites (A–C). TSS, transcription start site. B,
sequences of and surrounding SOX-A, -B, and -C representing the EMSA
probes used in Fig. 3. Gray shading highlights the SRY/SOX binding sites.
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lanes 8 and 9). As expected, mutation of both sites obliterated
the binding entirely (Fig. 3B, lanes 11 and 12). These data sug-
gest that SOX-B represents a high affinity binding site to which
the SOX proteins predominantly bind. In contrast, SOX-A
appears to be a low affinity site to which SOX9 binds only if
SOX-B is intact and occupied by another SOX9 molecule.
SOX9 but Not SRY Activates the Pgds Promoter—Binding
of SRY and SOX9 to these sequences suggested that these tran-
scription factors are able to transactivate thePgds promoter. To
validate this possibility, we used HEK293 cells and co-trans-
fected either Sry or Sox9 expression plasmids together with the
Pgds promoter fragment driving the luciferase gene. Expres-
sion of SOX9 and SRY was confirmed by Western blot anal-
ysis (Fig. 4A). Surprisingly, increasing amounts of Sry
expression plasmid appeared to repress rather than activate
transcription (Fig. 4B, wt/Sry). However, this repression of
the wild type promoter mediated by SRY was not changed by
mutation of either or both SOX binding sites (Fig. 4B,
A-mut, B-mut, AB-mut/Sry), suggesting that it is a nonspe-
cific, binding site-independent effect.
In contrast, increasing amounts of Sox9 expression construct
resulted in activation of luciferase activity (Fig. 4B, wt/Sox9).
Introduction of mutations in any or both of the SOX binding
sites led to a complete loss of promoter activation by SOX9 (Fig.
4B, A-mut, B-mut, AB-mut/Sox9), indicating that SOX9 has to
bind as a dimer to an intact paired SOX site to activate the Pgds
promoter. In summary, only SOX9 dimers but not SOX9
monomers or monomeric SRY binding are sufficient for trans-
activation of the Pgds promoter.
Ectopic Sry Does Not Alter Endogenous Pgds Expression in
Vivo—Our in vitro data implied that SOX9 but not SRY is able
to activate Pgds transcription. To support the in vivo signifi-
cance of this hypothesis, we performed two types of experi-
ments. First, we made use of a transgenic mouse line in which
Sry is expressed under the control of the Hsp70.3 promoter
(39). These mice exhibit XX sex reversal with Sry being
expressed as early as 10 ts along the whole length of the gonad
(Fig. 5A). This is in contrast to endogenous Sry, which is first
detectable at around 13 ts in the center of XY genital ridges
FIGURE 4. SOX9activates thePgdspromoter as a dimer.HEK293 cells were
co-transfectedwithwild type (wt) ormutated (A-mut, SOX-Amutated; B-mut,
SOX-B mutated; AB-mut, SOX-A and SOX-Bmutated) Pgds promoter reporter
plasmids and increasing amounts of Sox9 and Sry expression plasmids,
respectively. A, Western blot analysis showing that transfected Sox9
(detectedwith an SOX9 antibody) and Sry (detectedwith an HA antibody)
are expressed in HEK293 cells. B, a luciferase assay demonstrated that activa-
tion was only achieved when both SOX binding sites are intact and SOX9
binds as a dimer. Results are given as relative activation of the reporter by the
expression constructs when compared with the empty vector (). Data rep-
resent the mean and standard deviation of three independent experiments.
FIGURE 5. Ectopic Sry is not sufficient to induce endogenousPgds expres-
sion. A and B, whole-mount in situ hybridization of male wild type (XY) and
sex-reversed Sry-transgenic (XX tg) genital ridges from10 to 17 ts for Sry (right
gonads) (A) and Pgds (left gonads) (B). Sry was expressed in XX transgenic
animals already at 10 ts along the whole length of the genital ridge, in con-
trast to endogenous Sry in wild type XY genital ridges, whose expression
started at 13 ts. In both cases, Pgds expression was induced between 15 and
17 ts, suggesting that it is not directly regulated by SRY.
Regulation of Pgds Transcription by SOX9
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before extending to the poles (Fig. 5A) (3, 6). The onset of Sox9
expression is not altered in these transgenic mice, taking place
between 13 and 15 ts (39). Therefore, these mice provide a
unique model system with a time window of at least 8–10 h in
which only Sry but not Sox9 is expressed. Using this mouse
model, we investigated whether endogenous Pgds expression is
altered by the ectopic expression of Sry. Whole-mount in situ
hybridization of genital ridges from tail somite-staged mice
revealed that Pgds expression is first detectable at 15 ts both in
wild type XY as well as in transgenic XX genital ridges (Fig. 5B).
Therefore, ectopic expression of Sry is not sufficient to change
the expression pattern of Pgds, supporting our hypothesis that
Pgds is not directly regulated by SRY.
SOX9 Binds in Vivo to the Pgds Promoter—In a second series
of experiments, we used in vivo ChIP assay with isolated 11.5
dpc XX and XY genital ridges, respectively. Any transcription
factor that functions as a direct activator of Pgds in vivo would
be expected to be associated with the identified promoter frag-
ment in Sertoli cell nuclei. To test whether SRY and/or SOX9
bind to the Pgds promoter in vivo, immunoprecipitation was
carried out with antibodies specific for mouse SRY and SOX9.
As a control, primers were chosen that amplify a region2 kb
upstream of the Pgds transcription start site without any puta-
tive SOX sites (Fig. 6, PCR1) in comparison with the region
encompassing the characterized paired SOX site (Fig. 6, PCR2).
No enrichment of either of the fragments was found in XX or
XY genital ridges when immunoprecipitated with the SRY-spe-
cific antibody. Similarly, no SOX9 was bound to the upstream
region in XX andXY genital ridges or to the paired SOX sites in
XX genital ridges. However, SOX9 clearly occupied the paired
SOX sites in XY genital ridges (Fig. 6). Altogether, these results
demonstrated that SOX9 binds in vivo to the paired SOX bind-
ing sites in the Pgds promoter and is therefore likely to be
responsible for its male-specific expression.
DISCUSSION
The involvement of PGD2 in male sex determination has
been documented in several studies (6, 26, 27). PGD2, via the
binding to its specific receptor DP (prostaglandin D receptor),
is necessary and sufficient to recruit supporting cells that do not
express Sry to express Sox9 and its downstream targetAmh and
subsequently differentiate into Sertoli cells (6). Previous studies
involving XX↔ XY chimeras have shown that the number of
Sertoli cells has to reach a certain threshold to guarantee testis
development (24, 25). The paracrine signaling via PGD2 could
function as an important backup mechanism in case of
impaired Sry function to ensure that the Sertoli cell number
threshold is reached and male sexual differentiation will
commence.
Several studies investigated the regulation of human PGDS
transcription with relation to its expression in the brain and its
involvement in sleep regulation, pain response, and inflamma-
tion (40–42). Themolecules identified to be responsible for the
activation or repression of its expression in these cells such as
Notch, Hes-1, and AP-2 (40, 41) do not show any sex-specific
expression within the developing gonad based on Affymetrix
gene chip analysis (43–45),4 suggesting that SOX9might be the
critical factor for sex-specific expression in the testis, whereas
other factors play a more general role.
In this study, we aimed to shed light on the molecular mech-
anisms of male-specific Pgds expression during testis develop-
ment. By whole-mount and section ISH, we showed that Pgds,
like Sry and Sox9, is expressed in a similar dynamic spatio-
temporal expression pattern in the developing mouse gonads
with the onset of expression in the center of the genital ridges
and extending to the poles. Its expression starts soon after Sry
and Sox9 in the same cells, namely the Sertoli cell lineage. Sur-
prisingly, in contrast to published data (27), we could not detect
any Pgds transcripts in germ cells by using paraffin section ISH.
This might be due to the different techniques used: indirectly
using whole-mount ISH followed by paraffin embedding and
sectioning (27) versusdirect section ISHonparaffin-embedded,
sectioned whole embryos in this study.
Analysis of the Pgds promoter revealed a functional paired
SRY/SOX recognition site Interestingly, incubation with the
SRY protein resulted in the formation of only one complex, in
contrast to SOX9, which yielded two complexes, suggesting
that SRY is capable of binding one of the two sites, and SOX9
binds either as amonomer to one site or as a dimer to both sites.
Paired SOX sites that are recognized by SOX9 have been
described for almost all Sox9 target genes identified so far (7,
35–38). Most of these genes, such as Col2a1, matrilin-1,
Col11a2, and Col27a1, play a role in chondrogenesis. Their
paired SOX regulatory sequences are invariably arranged in
4 A. Jackson and P. Koopman, unpublished data.
FIGURE 6. SOX9, but not SRY, binds to thePgdspromoter in vivo.Chroma-
tin immunoprecipitation ofmale (M) and female (F) genital ridges at 11.5 dpc
with antibodies specific to SOX9 and SRY, respectively. Enrichment of the
region containing the paired SOX site (PCR2) when compared with an
upstream region without SOX consensus site (PCR1) is shown by PCR.
Regions, paired SOX binding site, and primer pairs (open arrowheads) used in
PCR are depicted below (not in scale). Genomic DNA before immunoprecipi-
tation (input)wasusedaspositive control, andPCRwithoutDNA template ()
was used as negative control.
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opposite orientation to each other and separated by 3 or 4 bp.
The paired SOX site identified in the Pgds promoter exhibits
the same features. However, mutation analysis uncovered an
important functional difference. In contrast to the chondro-
genic-specific enhancers in which mutation of either site com-
pletely prevented binding of SOX9, the paired site identified in
the Pgds promoter contains one high affinity site (SOX-B), the
occupancy of which facilitates binding of a second SOX9 mol-
ecule to the adjacent low affinity site (SOX-A). We found that
mutation of SOX-A does not affect SOX9 binding to SOX-B. A
similar scenario has been described for a SOX10 paired binding
site in the promoter regulating expression of the gene encoding
myelin Protein zero (P0) (46). It has been hypothesized earlier
that SOX9 cooperative dimerization is required for chondro-
genesis but not for sex determination (47). However, our results
and studies showing that the Amh promoter also contains a
paired SOX site (7) put this notion in question.
SOX9 and SOX10were shown to have a conserved DNA-de-
pendent dimerization domain located immediately N-terminal
to the highmobility group domain (46–48). This domain is not
present in mouse SRY. Accordingly, we found that SRY only
bound the high affinity site SOX-B in the Pgds promoter. Even
high protein concentration did not allow the binding to the low
affinity site SOX-A. In addition, transient transfection assays
indicated that the binding as a monomer, either by SRY or by
SOX9, is not sufficient to transactivate the Pgds promoter.
Clearly, SOX9 must bind and function as a dimer to activate
transcription.
The luciferase assays showed only a moderate induction of
the Pgds promoter-luciferase construct by co-transfection on
Sox9. However, we could detect relatively high basal luciferase
activity driven by the Pgds promoter fragment (12.8-fold
increase when compared with the empty luciferase construct).
Mutation of the paired SOX site reduced this activity to 2.1-
fold, demonstrating a high contribution of these sites to the full
promoter activity in 293 cells and therefore the only moderate
induction by exogenous Sox9.
Results from in vitro experiments such as transient transfec-
tion and EMSAs have to be treatedwith caution as theymay not
reflect the in vivo situation. To investigate whether Pgds is reg-
ulated by SRY in vivo, wemade use of a transgenicmouse line in
which ectopic Sry precedes Sox9 expression by at least 8 h.
EndogenousPgds expressionwas not altered in thesemice, sug-
gesting that SRY does not regulate its transcription directly.
However, it could also be due to the lack of a specific SRY
partner protein at these early time points whose expression is
independent of Sry. The second type of in vivo data is based on
ChIP. With this technique, we were able to convincingly dem-
onstrate that SOX9 binds in vivo at the right time to the paired
SOX binding site within the Pgds promoter. In contrast, with
the SRY antibody, we could not detect an enrichment of the
region including the paired SOX sites, suggesting that SRY does
not bind to this element in vivo at 11.5 dpc.
The production of PGD2 by PGDS in response to SOX9 in
turn activates Sox9 transcription (6), forming a positive feed-
back loop likely to play a role in maintaining Sox9 expression
and therefore Sertoli cell character. In addition to PGD2, the
transcription factorWT1 has been shown to be responsible for
continued Sox9 expression during testis development (49).
How far these two pathways interact has not been investigated
to date. However, given the fact that the maintenance of Sox9
expression is essential for testis cord integrity and therefore
proper testis development, it would not be surprising if it would
be under the control of several independent regulatory
mechanisms.
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